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alone. These results corresponded to an incremental cost-
effectiveness ratio (ICER) equivalent to SR20,423 (US$5,439)
per life-year gained and SR21,857 (US$5,821) per QALY gained.
Sensitivity analyses showed these results to be robust under a
range of plausible assumptions. CONCLUSIONS: Adjuvant
treatment with trastuzumab in HER2+ early breast cancer was
estimated to be a cost-effective treatment option over patients’
lifetimes in Saudi Arabia, attributed to improvements in life
expectancy and QALYs that translate into a high net beneﬁt to
the society.
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OBJECTIVES: To evaluate the cost-effectiveness of lapatinib plus
capecitabine (L + C) vs. currently used regimens in Finland for
women with HER2+ metastatic breast cancer which has pro-
gressed following trastuzumab treatment. METHODS: A
survival analysis model with a lifetime timeframe was used to
calculate expected costs, Life Years (LYs), and Quality Adjusted
Life Years (QALYs) for L + C vs. usual care in women with
HER2+ MBC who have progressed following trastuzumab treat-
ment. Usual care was represented as a weighted average of
currently-used treatments in Finland, including continued
trastuzumab-based therapy (50%) and single-agent chemo-
therapy (50%). The effectiveness of L + C and single-agent che-
motherapy was based on data from a phase III randomized open
label multi-centre trial comparing L + C with capecitabine alone
in women with HER2+ MBC who had received prior treatment
with an anthracycline, a taxane, and trastuzumab. Effectiveness
of trastuzumab-based therapy was based on a pooled analysis of
data from published studies. The analysis was performed from a
societal perspective. Costs were obtained from ofﬁcial price-lists.
Utilities were obtained from international publications. Costs
and outcomes were discounted at 5%, consistent with Finnish
guidelines. RESULTS: Compared with usual care, treatment with
L + C yields an additional 0.216 LYs and 0.157 QALYs at an
incremental cost of €8310. Cost-effectiveness of L + C vs. usual
care is €38,481 per LY gained and €52,911 per QALY gained.
The cost-effectiveness of L + C vs. usual care is sensitive to the
proportion of usual care patients who receive continued trastu-
zumab vs. single-agent chemotherapy. Assuming there are 130
candidates for L + C in Finland each year, the budget impact of
L + C is approximately €1M€ per year. CONCLUSIONS: For
patients with HER2+ MBC who have progressed on trastu-
zumab, treatment with L + C meets an unmet clinical need and is
cost-effective in this setting. IV administered treatment can cause
over 12,000€ additional costs per year compared with oral
formulations.
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OBJECTIVES: A randomized phase III trial of Capecitabine/
Cisplatin (XP) versus continuous infusion of 5-FU/Cisplatin (FP)
as ﬁrst-line therapy in patients with advanced gastric cancer
(AGC) met its primary endpoint of non-inferior progression-free
survival (PFS). There was a trend toward superior efﬁcacy with
XP in terms of both PFS and response rates. An economic assess-
ment was conducted in Spain to compare the costs of both
therapies considered unit costs and medical resource consump-
tion for year 2007. METHODS: Direct medical costs were esti-
mated from the Spanish National Healthcare System perspective.
The therapies costs were estimated based on the clinical trial
results on actual dose and the number of administrations, and
unit costs in different hospitals in Spain. The adverse event (AE)
proﬁles were used to estimate the costs of treating AEs. An expert
panel estimated treatment patterns and costs of treating major
AEs. Indirect costs for time and travel for drug administration
were also estimated. RESULTS: Annual pharmacologic cost in
the XP arm were estimated to be €1333 greater than in the XP
arm, but drug administration costs and AE costs were lower in
the XP arm (€2575 and €27, respectively). Overall, direct and
indirect medical costs were estimated at €2688 in the XP arm and
at €4014 in the FP arm. According to budget impact results, 1.58
patients are likely to be treated with XP for each patient treated
with FP. CONCLUSIONS: In Spain, oral capecitabine reduce the
number and time spent in infusion visits, and would produce
signiﬁcant direct medical cost savings in the treatment of patients
with AGC. Given the trend to superior efﬁcacy, the estimate
direct and indirect cost savings, and the convenience of oral
treatment, XP treatment would be considered less costly than FP
treatment for AGC from both a health care system and a societal
perspective.
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OBJECTIVES: Bone is the most common site for metastasis in
cancer and bone metastases (BM) result in considerable morbid-
ity and complex demands on health care resources. Bisphospho-
nates have been shown to treat and reduce skeletal-related events
(SREs), which reduce quality-of-life and increase the risk of
death. The aim of this study was to evaluate the cost-effectiveness
of clodronate and zoledronate in the prevention of SREs in
patients with BM. METHODS: We developed a Markov model
to represent a cohort of patients diagnosed with BM in order to
determine the cost-effectiveness of the studied therapeutic alter-
natives. The model has four health states: without SRE, with SRE
(i.e., pathologic fracture, radiotherapy or surgery, and hypercal-
cemia), osteonecrosis and death. Transition probabilities came
from SREs incidence rate meta-analysis previously performed by
our group. Economical data were obtained from national data-
bases. Univariate and multivariate sensibility analyses were used
to determine the robustness of the pharmacoeconomic model. We
used the public health perspective. Costs were presented in 2007
Brazilian Reais (1R$ = 1.60US$) RESULTS: BM treatment total
cost in Brazil (on average, per patient) in ﬁve years (base case)
was R$46,313 with clodronate and R$50,319 with zoledronate.
Drug cost was the most inﬂuential item in the overall cost of BM
treatment (>90%). In a ﬁve-year time-horizon, clodronate and
zoledronate generated (on average, per patient) 2.00 and 1.90
QALYs, respectively. In this same time-horizon, clodronate and
zoledronate also generated (on average, per patient) 1.81 and
1.76 SRE free-years, respectively. When we analyzed clodronate
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